NEWS
Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
2 minutes ago, 4:30 AM PST
Via GlobeNewswire
APTO
Share
• TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites
• Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populations
• Study execution update is expected during ASH 2024
2 minutes ago, 4:30 AM PST
Via GlobeNewswire
APTO
Share
• TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sites
• Favorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to potentially address larger AML populations
• Study execution update is expected during ASH 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2535Followers
107Following
27KVisitors
Follow